The 2.5 mg starting dose is a 4-week ramp
Preclinical work also points to applications in reproductive health (e.g., PCOS-related fertility improvements) and oncology, where observational studies link GLP-1 use to lower risks of obesity-related cancers
Subsequent case reports have documented similar concerning events, including the Gulak and Murphy series describing a 70-year-old male who regurgitated large-volume particulate contents during laryngoscopy two days after semaglutide cessation [5]
Semaglutide Has an FDA Indication for MASH Wegovy received FDA accelerated approval for MASH (metabolic dysfunction-associated steatohepatitis) in August 2025
It is a state of metabolic alert, where the bodys ability to process glucose is becoming impaired, often due to insulin resistance
Taken together, an effective treatment to limit vitiligo progression and recurrence needs to improve i) the EAS enzymes (i.e., GPx, TrxR, and CAT)